Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration.

ABSTRACT:

Objectives

To evaluate clinical response by baseline disease duration using 2-year data from the AMPLE trial.

Methods

Patients were randomised to subcutaneous abatacept 125 mg weekly or adalimumab 40 mg bi-weekly, with background methotrexate. As part of a post hoc analysis, the achievement of validated definitions of remission (Clinical Disease Activity Index (CDAI) ≤2.8, Simplified Disease Activity Index (SDAI) ≤3.3, Routine Assessment of Patient Index Data 3 (RAPID3) ≤3.0, Boolean score ≤1), low disease activity (CDAI <10, SDAI <11, RAPID3 ≤6.0), Health Assessment Questionnaire-Disability Index response and American College of Rheumatology responses were evaluated by baseline disease duration (≤6 vs >6 months). Disease Activity Score 28 (C-reactive protein) <2.6 or ≤3.2 a

SUBMITTER: Schiff M 

PROVIDER: S-EPMC4838764 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature